论文部分内容阅读
目的分析依达拉奉、高压氧治疗急性脑梗死(ACI)对患者促血管生成素-Ⅱ(Ang-2)、血管内皮生长因子(VEGF)的影响。方法选取ACI患者92例,将其随机分成研究组和常规组,每组46例。两组均予以基础治疗,常规组在此基础上加用依达拉奉治疗,研究组在常规组基础上进行高压氧治疗,比较两组患者的有效率、Ang-2、VEGF及日常生活能力。结果 (1)有效率:常规组为80.43%,研究组为95.65%,差异有统计学意义(P<0.05);(2)研究组治疗后2、4周的Ang-2水平均高于常规组,差异有统计学意义(P<0.05);(3)治疗后2周,研究组VEGF水平明显上升,4周后略微降低,但均高于常规组,差异有统计学意义(P<0.05);(4)研究组治疗后2、4周的日常生活能力分值高于常规组,差异有统计学意义(P<0.05)。结论 ACI患者采用依达拉奉与高压氧结合治疗,能促进患者Ang-2、VEGF水平的改善,提升疗效,值得临床推广。
Objective To investigate the effects of edaravone and hyperbaric oxygen on angiopoietin-2 (Ang-2) and vascular endothelial growth factor (VEGF) in patients with acute cerebral infarction (ACI). Methods 92 patients with ACI were selected and randomly divided into study group and conventional group, with 46 cases in each group. The two groups were given basic treatment. The conventional group was treated with edaravone. The study group was treated with hyperbaric oxygen on the basis of conventional group. The effective rate, Ang-2, VEGF and daily living ability were compared between the two groups . Results (1) The effective rate was 80.43% in the conventional group and 95.65% in the study group, the difference was statistically significant (P <0.05). (2) The Ang-2 levels in the study group were higher than those in the routine (P <0.05). (2) After 2 weeks of treatment, the level of VEGF in the study group increased significantly, slightly decreased after 4 weeks, but both were significantly higher than those in the conventional group (P <0.05), the difference was statistically significant ); (4) The scores of daily living ability of the study group after 2 and 4 weeks of treatment were higher than those of the conventional group, the difference was statistically significant (P <0.05). Conclusion The combination of edaravone and hyperbaric oxygen in patients with ACI can promote the improvement of Ang-2 and VEGF levels in patients with ACI, which is worthy of clinical promotion.